garenoxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antibacterials, nalidixic acid derivatives	4053	194804-75-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

garenoxacin
ganefloxacin
garenfloxacin
garenoxacin mesilate hydrate
garenoxacin mesilate
garenoxacin mesylate
geninax

a des-fluoro(6) quinolone with antibacterial activity

Molecular weight: 426.42
Formula: C23H20F2N2O4
CLOGP: 3
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 78.87
ALOGS: -4.26
ROTB: 5

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	1 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.23 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.25 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	10 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	0.92 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	GRK2,PDK1,PDK2,PDK4	4
kinase-selectivity-class	ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PIK3CD,PRKDC,STK33,TGFBR1,TTK	13
pfas-class	PFAS structural alert (1 = True, 0 = False)	1

Approvals:

Date	Agency	Company	Orphan
May 30, 2007	PMDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	44.60	39.10	21	757	139313	110449208
Pneumonia	41.70	39.10	40	738	876674	109711847

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01MA19	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors
MeSH PA	D059005	Topoisomerase II Inhibitors
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory drug
CHEBI has role	CHEBI:36047	antibacterial drug

Related Drugs by ATC class:

J01MA Fluoroquinolones 22 drugs

ciprofloxacin delafloxacin enoxacin fleroxacin gatifloxacin gemifloxacin grepafloxacin lascufloxacin levofloxacin lomefloxacin moxifloxacin norfloxacin show all 22 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peritonsillar abscess	indication	15033003
Sinusitis	indication	36971009
Bacterial pneumonia	indication	53084003	DOID:874
Infective otitis media	indication	312218008
Infective laryngitis	indication	312423006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.37	acidic
pKa2	8.85	Basic
pKa3	0.41	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D02540	KEGG_DRUG
C1507405	UMLSCUI
CHEBI:131716	CHEBI
CHEMBL215303	ChEMBL_ID
DB06160	DRUGBANK_ID
C419689	MESH_SUPPLEMENTAL_RECORD_UI
124093	PUBCHEM_CID
12402	IUPHAR_LIGAND_ID
8237	INN_ID
223652-90-2	SECONDARY_CAS_RN
V72H9867WB	UNII
CHEMBL3183451	ChEMBL_ID

Pharmaceutical products:

None